EcoDrugPlus

Solute Carrier Family 10 Member 2

Ensembl ID : ENSPSNG00000015215
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSPSNG00000021681
Gene Symbol: SLC18A2
3 Cross references
223 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSPSNG00000019972
Gene Symbol: SLC22A6
1 Cross references
490 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSPSNG00000020185
Gene Symbol: SLC22A8
3 Cross references
310 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSPSNG00000021618
Gene Symbol: SLC29A1
3 Cross references
284 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSPSNG00000019930
Gene Symbol: SLC5A1
1 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSPSNG00000014814
Gene Symbol: SLC5A2
3 Cross references
197 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSPSNG00000012418
Gene Symbol: SLC6A1
1 Cross references
276 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSPSNG00000017229
Gene Symbol: SLC6A2
3 Cross references
202 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSPSNG00000002215
Gene Symbol: SLC6A3
3 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSPSNG00000022384
Gene Symbol: SLC6A4
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSPSNG00000003705
Gene Symbol: SLC6A9
3 Cross references
207 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).